229474-82-2

Upstream product

• 195877-39-5 4-(2-benzyloxycarbonylamino-2-methoxycarbonyl-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 195877-38-4 4-(2-benzyloxycarbonylamino-2-carboxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 229474-84-4 4-(2-{[(S)-1-((R)-3-Cyclohexyl-2-ethanesulfonylamino-propionyl)-pyrrolidine-2-carbonyl]-amino}-3-hydroxy-3-methoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 195877-42-0 4-(2-benzyloxycarbonylamino-3-hydroxy-3-methoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 195877-41-9 3-benzyloxycarbonylamino-2-hydroxy-4-piperidin-4-yl-butyric acid methyl ester 
• 195877-40-8 4-(3-acetoxy-2-benzyloxycarbonylamino-3-cyano-propyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety

2-Amino-3-piperidin-4-yl-propionic acid containing peptidomimetics are potent protease inhibitors when combined with an appropriate keto-thiazole or keto-carboxylic acid moiety. A novel P1 residue in factor Xa and thrombin inhibitors has been found resulting in IC50 values as low as 0.048 μM, a factor of ten more potent than Argatroban. Starting with non-chiral synthetic routes, a new stereospecific route was developed as well as a new solid- phase method.